The outstanding results delivered by the Breathe Easy prospective study are consistent with our expectations, and for diseases such as pneumonia and asthma have even exceeded our expectations. This formal confirmation of ResApp’s algorithms’ robust performance will allow us to provide key diagnostic products in an array of clinical settings, especially in telehealth - one of the fastest growing segments in healthcare - where up to 50% of consultations are respiratory related”, said Tony Keating, CEO and Managing Director of ResApp. “We now have a solid dataset to underpin our forthcoming CE mark and TGA submissions which will propel the commercialisation of our products in Europe, Australia and the rest of the world outside the US. The successful completion of Breathe Easy also gives us additional data, experience and confidence as we finalise our US SMARTCOUGH-C-2 study.”
Are we reading the same thing???
- Forums
- ASX - By Stock
- RAP
- Ann: Positive Results for Australian Prospective Paediatric Study
Ann: Positive Results for Australian Prospective Paediatric Study, page-104
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
-
- There are more pages in this discussion • 266 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online